

**AURO LABORATORIES LIMITED**  
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR  
BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

**ANNEXURE - I**

| PART - I   |  | Rs. In Lakhs)           |                           |   |                         |                         |
|--|--|-------------------------|---------------------------|---|-------------------------|-------------------------|
| <b>STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2019</b> |  |                         |                           |   |                         |                         |
| Sr. No.  | Particulars  | 3 Months ended          | Preceding 3 Months ended  | Corresponding 3 Months ended in the Previous Year | For the year Ended      | Previous Year Ended     |
|  |  | 31.03.2019<br>(audited) | 31.12.2018<br>(Unaudited) | 31.03.2018<br>(audited)                           | 31.03.2019<br>(Audited) | 31.03.2018<br>(Audited) |
| <b>1</b>   | <b>Income from Operations</b>  |                         |                           |   |                         |                         |
|  | (a) Net Sales/Income from Operations (Net of excise duty)  | 1,153.02                | 1227.61                   | 1,127.82  | 4,682.31                | 4,079.40                |
| <b>2</b>   | <b>Other Income</b>  | 59.34                   | 7.28                      | 22.65   | 95.82                   | 51.39                   |
| <b>3</b>   | <b>Total Revenue (1 + 2)</b>   | 1,212.36                | 1,234.89                  | 1,150.47  | 4,778.13                | 4,130.79                |
| <b>4</b>   | <b>Expenses</b>  |                         |                           |   |                         |                         |
|  | a. Consumption of raw material   | 621.14                  | 793.71                    | 660.79  | 3,013.82                | 2,461.65                |
|  | b. Purchase of Stock-in-trade  | 23.87                   | -                         | 1.24  | 24.91                   | 4.06                    |
|  | c. (Increase) / decrease in Finished Goods stock in trade and work in progress                   | -8.65                   | (61.63)                   | (92.49)   | (176.59)                | 6.24                    |
|  | d. Employee benefits expense   | 132.32                  | 96.67                     | 171.92  | 407.07                  | 369.54                  |
|  | e. Finance Cost  | 12.57                   | 18.01                     | 5.03  | 72.22                   | 108.85                  |
|  | f. Depreciation and amortisation expenses  | 22.42                   | 28.00                     | 20.11   | 100.92                  | 93.11                   |
|  | g. Other Expenses  | 177.54                  | 175.61                    | 178.15  | 728.89                  | 614.60                  |
|  | <b>Total Expenses (4)</b>  | 981.21                  | 1,050.37                  | 944.75  | 4,171.24                | 3,658.05                |
| <b>5</b>   | <b>Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)</b>                | 231.15                  | 184.52                    | 205.72  | 606.89                  | 472.74                  |
| <b>6</b>   | <b>Exceptional items</b>   |                         |                           | -   |                         | -                       |
| <b>7</b>   | <b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>                                | 231.15                  | 184.52                    | 205.72  | 606.89                  | 472.74                  |
| <b>8</b>   | <b>Extraordinary items</b>   | -                       | -                         | -   |                         |                         |
| <b>9</b>   | <b>Profit / (Loss) before tax (7 ± 8)</b>  | 231.15                  | 184.52                    | 205.72  | 606.89                  | 472.74                  |
| <b>10</b>  | <b>Tax expense</b>   | -                       | -                         | -   |                         | -                       |
|  | (a) Current tax expenses for current year  | 67.76                   | 46.13                     | -   | 161.69                  | 127.34                  |
|  | (b) MAT credit (where applicable)  | -                       | -                         | -   |                         | -                       |
|  | (c) Defferered tax   | 5.25                    | -                         | -   | 5.25                    | (7.56)                  |
| <b>11</b>  | <b>Profit / (Loss) for the period from continuing operation (9± 10)</b>                          | 158.15                  | 138.39                    | 205.72  | 439.95                  | 352.96                  |
| <b>12</b>  | <b>Profit / (Loss) for discontinuing operations</b>  | -                       | -                         | -   |                         | -                       |
| <b>13</b>  | <b>Tax expense of discontinuing operations</b>   | -                       | -                         | -   |                         | -                       |
| <b>14</b>  | <b>Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)</b>                         | 158.15                  | 138.39                    | 205.72  | 439.95                  | 352.96                  |
| <b>15</b>  | <b>Other Comprehensive Income</b>  | 8.11                    | (1.34)                    | 2.75  | 8.11                    | 4.63                    |
| <b>16</b>  | <b>Total Comprehensive Income for the period (14 ± 15)</b>                                       | 166.26                  | 137.05                    | 208.47  | 448.06                  | 357.59                  |
| <b>17</b>  | <b>Paid-up equity share capital</b><br>(Face value of Rs. 10 each)                               | 623.25                  | 623.25                    | 623.25  | 623.25                  | 623.25                  |
| <b>17</b>  | <b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)</b> | -                       | -                         | -   | 603.14                  | 251.30                  |
| <b>18</b>  | <b>Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):</b>                         |                         |                           |   |                         |                         |
|  | (a) Basic  | 2.54                    | 2.22                      | 3.30  | 7.06                    | 5.66                    |
|  | (b) Diluted  | 2.54                    | 2.22                      | 3.30  | 7.06                    | 5.66                    |



## Auro Laboratories Limited

| Statement of Assets and Liabilities (Ind AS)   |                     |                     |
|--|---------------------|---------------------|
| Particulars                                    | (Rs. In Lakh)       |                     |
|  | As at<br>31/03/2019 | As at<br>31/03/2018 |
|  | Audited             | Audited             |
| <b>A ASSETS</b>                                |                     |                     |
| <b>1. Non-Current Assets</b>                   |                     |                     |
| (a) Property, Plant and Equipment              | 1,458.62            | 1,302.33            |
| (b) Capital Work -in-Progress                  | 11.60               | 107.29              |
| (c) Investment Property                        | -                   | -                   |
| (d) Financial Assets                           |                     |                     |
| (i) Investments                                | 4.88                | 4.88                |
| (ii) Loans                                     | -                   | -                   |
| (iii) Others                                   | -                   | -                   |
| (e) Other non-current assets - Capital Advance | -                   | -                   |
| <b>2. Current assets</b>                       |                     |                     |
| (a) Inventories                                | 337.38              | 149.10              |
| (b) Financial Assets                           | -                   | -                   |
| (i) Investments                                | -                   | -                   |
| (ii) Trade Receivables                         | 850.38              | 837.49              |
| (iii) Cash and cash equivalents                | 335.88              | 179.74              |
| (iv) Bank balances other than (iii) above      | 74.88               | 45.27               |
| (v) Loans                                      | -                   | -                   |
| (vi) Others                                    | 272.92              | 414.24              |
| (c) Other Current Assets                       | -                   | -                   |
| <b>TOTAL ASSETS</b>                            | <b>3346.54</b>      | <b>3040.34</b>      |
| <b>B EQUITY AND LIABILITIES</b>                |                     |                     |
| <b>1. Equity</b>                               |                     |                     |
| (a) Equity Share Capital                       | 623.25              | 623.25              |
| (b) Other Equity                               | 1,117.95            | 674.52              |
| <b>2. Liabilities</b>                          |                     |                     |
| (I) Non-Current Liabilities                    |                     |                     |
| (a) Financial Liabilities                      | 614.93              | 617.84              |
| (i) Other Financial Liabilities                | 194.50              | 302.00              |
| (b) Provisions                                 | -                   | -                   |
| (c) Deferred Tax Liabilities (Net)             | 149.67              | 144.41              |
| (II) Current Liabilities                       |                     |                     |
| (a) Financial Liabilities                      |                     |                     |
| (i) Trade Payables                             | 518.32              | 530.11              |
| (b) Other Current Liabilities                  | 78.10               | 73.28               |
| (c) Provisions                                 | 49.82               | 74.93               |
| (d) Current Tax Liabilities (net)              | -                   | -                   |
| <b>TOTAL EQUITY AND LIABILITIES</b>            | <b>3346.54</b>      | <b>3040.34</b>      |



**Notes:**

- 1) The above audited financial results for the quarter and year ended 31st March, 2019 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 23rd May, 2019.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
- 4) Figures of last Quarter are the balanceing figures between audited figures in respect of the full financial year and the publised year to the date upto the third quarter of the current financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS**

**AURO LABORATORIES LIMITED**

**SHARAT DEORAH**  
**MANAGING DIRECTOR**  
**DIN NO. 00230784**



**Place : Mumbai**  
**Date : 23.05.2019**



**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS

To,  
The Board of Directors,  
Auro Laboratories Limited.

1. We have audited the accompanying Statement of Standalone Financial Results of Auro Laboratories Ltd. ("the company") for the quarter and year ended March 31, 2019, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.
2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2019, has been compiled from the related interim condensed standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2019, had been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013 read with rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim condensed standalone financial statements and annual standalone financial statements.

Further, we report that the figures for the quarter ended March 31, 2019 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2019 and the published year to date figures up to December 31, 2018 being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated above as required under the Listing Regulations and circular.

3. We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement(s).





**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS


An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statements.

We believe that the evidence obtained by us, is sufficient appropriate to provide a basis for our audit opinion.

4. In our opinion and the best of our information and according to the explanations given to us, the Statement:
- (i) is presented in accordance with requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, and
  - (ii) give a true and fair view, in conformity with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2019.

For Khurdia Jain & Co.  
Chartered Accountants  
(Firm Reg. No. 120263W)

Sampat Khurdia  
Partner  
Membership No. 033615  
Place: Mumbai  
Date: 23/05/2019





**Auro Laboratories Limited**

314, T.V. Industrial Estate, S.K. Ahire Marg,  
Worli, Mumbai - 400 030. India  
Tel. : + 91 22 6663 5456  
Fax : +91 22 6663 5460  
E-mail : auro@aurolabs.com  
Web : www.aurolabs.com

Date: May 23, 2019.

To  
**BSE Limited,**  
**Corporate Relationship Department,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Reg. Off. / Mfg. Unit :  
K-56, M. I. D. C. Tarapur,  
Dist. Palghar, Maharashtra - 401506.  
CIN No. L33125MH1989PLC051910

Reg: Security Code No. 530233

**Sub: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby confirm that the Audit Reports by M/s. Khurdia Jain & Co, Chartered Accountants, Mumbai on the Audited Financial Results of the Company for the quarter and year ended March 31, 2019 is with Unmodified Opinion.

Kindly take the same on your record.

Thanking you,

For **AURO LABORATORIES LIMITED**

  
**SHARAT DEORAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
[DIN: 00230784]

